Somatuline Autogel Preference and Health Economy Study
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to assess which method of lanreotide Autogel administration
patients with neuroendocrine tumours prefer - self/partner administrations or healthcare
provided administrations. The study will also assess if self/partner administration can be
performed without loss of efficacy and with a preserved safety profile. The impact of
self/partner administration on resource utilisation and costs will be studied. In addition,
we will also assess the healthcare provider's experience of the two administration practices.